Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

1.6K
Here, we describe a method for transducing human T cells with luciferase to facilitate in vivo tracking of bispecific antibody-induced T cell trafficking to tumors in studies to evaluate the anti-tumor efficacy and mechanism of T cell-engaging bispecific antibodies.
1.6K
Orthogonal Protein Purification Facilitated by a Small Bispecific Affinity Tag10:32

Orthogonal Protein Purification Facilitated by a Small Bispecific Affinity Tag

17.4K
A novel and highly efficient two-step affinity chromatography protocol has been developed and is described in detail. The method is based on a small purification tag with two inherent affinities and is applicable to a wide range of target proteins with different properties.
17.4K
An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors02:44

An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors

555
This video demonstrates a method for tracking bispecific antibody-induced T cell trafficking to tumors in a mouse model. Luciferase-transduced effector T cells are injected into a mouse with a subcutaneous tumor cell xenograft. Bispecific antibodies are then introduced, binding to T cells and the tumor cells. The localization of the T cells is tracked using bioluminescent imaging, with the magnitude of the signal indicating the extent of T cell infiltration into the...
555
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

7.7K
Here, we present a protocol to measure KDM1A target engagement in a human or animal cell, tissue or blood samples treated with KDM1A inhibitors. The protocol employs chemoprobe tagging of the free KDM1A enzyme and direct quantification of the target occupation using chemoprobe-based immunoassays and can be used in preclinical and clinical...
7.7K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

9.2K
Here, we present a protocol to produce a bispecific antibody GPC3-S-Fab in Escherichia coli. The purified GPC3-S-Fab has potent cytotoxicity against GPC3 positive liver cancer...
9.2K
Using High Content Imaging to Quantify Target Engagement in Adherent Cells07:23

Using High Content Imaging to Quantify Target Engagement in Adherent Cells

9.0K
Measurements of drug target engagement are central to effective drug development and chemical probe validation. Here, we detail a protocol for measuring drug-target engagement using high content imaging in a microplate-compatible adaption of the cellular thermal shift assay...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

HemaSphere·2026
Same author

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Blood·2026
Same author

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

Blood·2026
Same author

Intra-subtype heterogeneity shapes treatment response in <i>KMT2A</i>-rearranged ALL across all age groups.

HemaSphere·2026
Same author

Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial.

Annals of hematology·2026
Same author

Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia.

Bone marrow transplantation·2025

Related Experiment Video

Updated: Jan 20, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.6K

Clinical Experience with Bispecific T Cell Engagers.

Nicola Gökbuget1

  • 1Department of Medicine II, University Hospital Goethe University, Theodor Stern Kai 7, 60590, Frankfurt, Germany. goekbuget@em.uni-frankfurt.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|September 2, 2019
PubMed
Summary

Blinatumomab, a bispecific T cell engager targeting CD19, shows clinical activity in relapsed/refractory B-cell malignancies like acute lymphoblastic leukemia. Understanding resistance mechanisms is key for future applications.

Keywords:
Acute lymphoblastic leukemiaAntibodyBispecificBlinatumomabReview

More Related Videos

Orthogonal Protein Purification Facilitated by a Small Bispecific Affinity Tag
10:32

Orthogonal Protein Purification Facilitated by a Small Bispecific Affinity Tag

Published on: January 16, 2012

17.4K
An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors
02:44

An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors

555

Related Experiment Videos

Last Updated: Jan 20, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.6K
Orthogonal Protein Purification Facilitated by a Small Bispecific Affinity Tag
10:32

Orthogonal Protein Purification Facilitated by a Small Bispecific Affinity Tag

Published on: January 16, 2012

17.4K
An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors
02:44

An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors

555

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Bispecific T cell engagers (BiTEs) are engineered antibodies targeting tumor antigens and CD3+ T cells.
  • Blinatumomab targets the pan-B cell marker CD19, activating T cells against malignant B cells.

Purpose of the Study:

  • To evaluate the clinical activity of blinatumomab in relapsed/refractory (R/R) non-Hodgkin's Lymphoma (NHL) and R/R acute lymphoblastic leukemia (ALL).
  • To assess blinatumomab's efficacy in ALL patients with minimal residual disease and in de novo ALL.
  • To identify potential mechanisms of resistance and associated unfavorable factors.

Main Methods:

  • Clinical trials were conducted to test the efficacy of blinatumomab.
  • Patient populations included R/R NHL, R/R ALL, and ALL with minimal residual disease.
  • Toxicities, resistance mechanisms, and prognostic factors were investigated.

Main Results:

  • Blinatumomab demonstrated clinical activity in R/R NHL and R/R ALL, including ALL patients with minimal residual disease.
  • Neurologic events and cytokine release syndrome were identified as key toxicities.
  • Higher leukemia load, later disease stage, regulatory T cell upregulation, and PD-1/PD-L1 expression were associated with unfavorable outcomes or resistance.

Conclusions:

  • Blinatumomab shows promise as a T cell-engaging therapy for B-cell malignancies, particularly ALL.
  • Further research is needed to fully elucidate resistance mechanisms and optimize treatment strategies.
  • Bispecific T cell engagers may potentially alter standard treatment algorithms in ALL and other cancers.